POAI Predictive Oncology Inc.

Nasdaq predictive-oncology.com


$ 0.79 $ 0.05 (6.25 %)    

Friday, 06-Dec-2024 14:10:12 EST
QQQ $ 525.87 $ 4.67 (0.89 %)
DIA $ 447.30 $ -1.52 (-0.34 %)
SPY $ 607.78 $ 1.15 (0.19 %)
TLT $ 94.35 $ 0.14 (0.15 %)
GLD $ 242.95 $ 0.09 (0.04 %)
$ 0.803
$ 0.80
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 0.55 - $ 3.76
149,873
na
5.35M
$ 1.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2024 09-30-2024 10-Q
2 08-13-2024 06-30-2024 10-Q
3 05-14-2024 03-31-2024 10-Q
4 03-28-2024 12-31-2023 10-K
5 11-13-2023 09-30-2023 10-Q
6 08-10-2023 06-30-2023 10-Q
7 05-15-2023 03-31-2023 10-Q
8 03-21-2023 12-31-2022 10-K
9 11-10-2022 09-30-2022 10-Q
10 08-11-2022 06-30-2022 10-Q
11 05-12-2022 03-31-2022 10-Q
12 03-31-2022 12-31-2021 10-K
13 11-10-2021 09-30-2021 10-Q
14 08-11-2021 06-30-2021 10-Q
15 05-12-2021 03-31-2021 10-Q
16 03-15-2021 12-31-2020 10-K
17 11-16-2020 09-30-2020 10-Q
18 08-13-2020 06-30-2020 10-Q
19 06-08-2020 03-31-2020 10-Q
20 04-01-2020 12-31-2019 10-K
21 11-15-2019 09-30-2019 10-Q
22 08-19-2019 06-30-2019 10-Q
23 05-15-2019 03-31-2019 10-Q
24 04-01-2019 12-31-2018 10-K
25 11-14-2018 09-30-2018 10-Q
26 08-14-2018 06-30-2018 10-Q
27 05-15-2018 03-31-2018 10-Q
28 04-02-2018 12-31-2017 10-K
29 11-14-2017 09-30-2017 10-Q
30 08-14-2017 06-30-2017 10-Q
31 05-15-2017 03-31-2017 10-Q
32 03-15-2017 12-31-2016 10-K
33 11-14-2016 09-30-2016 10-Q
34 08-12-2016 06-30-2016 10-Q
35 05-23-2016 03-31-2016 10-Q
36 03-16-2016 12-31-2015 10-K
37 11-13-2015 09-30-2015 10-Q
38 08-10-2015 06-30-2015 10-Q
39 05-18-2015 03-31-2015 10-Q
40 04-30-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 predictive-oncology-advances-evaluation-of-strategic-alternatives-exploring-multiple-potential-paths

As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, inclu...

 hc-wainwright--co-downgrades-predictive-oncology-to-neutral

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Predictive Oncology (NASDAQ:POAI) from Buy to Neutral.

 predictive-oncology-announced-that-the-company-is-working-with-a-strategic-advisor-has-initiated-a-process-to-evaluate-a-broad-range-of-strategic-alternatives

Q3 2024 and Recent Highlights:Announced the results of an additional study that successfully demonstrated the long-term stabili...

 predictive-oncology-q3-2024-gaap-eps-036-misses-026-estimate-sales-34569k-miss-35000k-estimate

Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of...

 hc-wainwright--co-initiates-coverage-on-predictive-oncology-with-buy-rating-announces-price-target-of-3

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Predictive Oncology (NASDAQ:POAI) with a Buy ra...

 predictive-oncology-q2-eps-068-up-from-098-yoy-sales-27872k-down-from-49011k-yoy

Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.68) per share. This is a 30.61 percent increase over losses ...

 predictive-oncology-has-expanded-the-available-applications-for-its-platform-to-account-for-patient-heterogeneity-de-risk-drug-discovery-and-accelerate-pipeline-development

Findings demonstrate real-world applications of Company's AI platform to support biomarker discovery, clinical trial optimi...

 predictive-oncology-exercises-warrants-for-126m-gross-proceeds

Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered...

 why-predicitive-oncology-stock-is-soaring

Predictive Oncology shares are blasting higher Thursday after the company announced it is expanding its AI and machine learning...

 reported-earlier-predictive-oncology-enters-biomarker-discovery-market-after-successful-retrospective-ovarian-cancer-study-yields-compelling-results-expands-aiml-driven-offering-to-include-novel-oncology-biomarker-discovery-to-predict-patient-outcomes-and-drug-response-in-oncology

Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in on...

Core News & Articles
Market-Moving News for July 25th
07/25/2024 13:01:55

EW: -24% | Edwards Lifesciences shares are trading lower after the company reported worse-than-expected Q2 sales results and is...

 predictive-oncology-introduces-new-technology-for-expressing-functional-and-stable-g-protein-coupled-receptors-gpcrs

Company files expansive intellectual property protection for "Membrane Protein Factory" to produce purified and biologi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION